“Albumin Extract for Dogs from Lipemic Plasma” by Chula Students and Faculty Wins Gold Medal and Innovation Award at Thailand Research Expo 2025 

The innovative project “Albumin Extract for Dogs from Lipemic Plasma,” developed by students and faculty from the Faculty of Veterinary Science at Chulalongkorn University, has been honored with a Gold Medal and High Distinction Innovation Award at the Thailand Research Expo 2025. By extracting dog-specific albumin from discarded lipemic plasma, this research not only addresses medical challenges in canine care but also offers a sustainable solution to veterinary waste management. The project stands out for its potential to transform waste into life-saving treatments for dogs, enhance veterinary care, and pave the way for further clinical and international developments.

“Albumin Extract for Dogs from Lipemic Plasma” an innovation developed by students and faculty members from the Faculty of Veterinary Science, Chulalongkorn University, received a Gold Medal and a High Distinction Innovation Award in the 2025 Higher Education Innovation Contest, held during the Thailand Research Expo 2025 from June 16–20, 2025, at Centara Grand and Bangkok Convention Centre, CentralWorld. Award recipients include: 

• Mr. Kunanon Rojratanachai 
• Mr. Natthaphong Sithprasert 
• Mr. Weerakan Suksareekit 
• Mr. Nattawat Phujaroen 
• Mr. Sophonwit Phumsanguan 
• Assoc. Prof. Dr. Sayamon Srisuwatanasakul, DVM 
• Assoc. Prof. Dr. Sariya Asawakarn, DVM 
• Assoc. Prof. Dr. Kongkiat Srisuwattanasakul, DVM 
• Dr. Suwarat Wadeerat, DVM 

  —all from the Faculty of Veterinary Science, Chulalongkorn University. 

Background and Innovation Insight 

Lipemic plasma (plasma with high fat content) is typically considered waste in veterinary blood banks due to its interference with laboratory diagnostics, degradation of blood product quality, and increased risk of transfusion side effects. Albumin, a critical protein used to treat shock, blood loss, burns, and hypoalbuminemia in dogs, is not currently available as a dog-specific product. Veterinarians often resort to using human albumin, which carries risks such as unwanted immune responses, reduced efficacy, and high costs. 

To address this, the research team sought to transform “waste” into “value” by extracting usable dog-specific albumin from discarded lipemic plasma. 

Extraction Process 

The process involves two main stages: 

1. Fat Removal – Optimizing the centrifugation process to reduce fat content in the plasma. 
2. Albumin Extraction and Purification – Using heat-induced precipitation to remove other proteins, followed by testing the yield, purity, and sterility of the extracted albumin. 

Turning Veterinary Waste into Life-Saving Dog Treatments 

This innovation redefines veterinary waste management by repurposing discarded lipemic plasma into a high-value medical product. It not only maximizes resource efficiency and reduces bio-waste but also provides multiple health benefits for dogs: 

• Offers safer and species-specific treatment alternatives, minimizing the immune side effects commonly seen with human albumin. 
• Enhances treatment efficacy, as species-specific albumin is more compatible and effective in canine physiology. 
• Improves outcomes for dogs experiencing critical conditions such as shock, blood loss, or low blood protein levels. 
• Reduces veterinary costs, enabling wider access to advanced care by repurposing discarded materials. 

“Albumin Extract for Dogs from Lipemic Plasma” is an innovative veterinary product developed to obtain pure, dog-specific albumin protein from lipemic plasma—a byproduct of blood donations with high fat content that is usually discarded. This process transforms what is typically considered waste in veterinary blood banks into a valuable medical treatment for dogs suffering from conditions such as shock, blood loss, burns, or low blood protein levels, providing a safer and more effective alternative to using human albumin in canine patients.

Advancing Canine Albumin with Clinical Testing and Global Partnerships 

The student and faculty research team plans to further develop the project by conducting clinical trials on actual canine patients to assess efficacy and safety. Collaborations are underway with multinational pharmaceutical companies for broader clinical testing, product registration for veterinary use, and potential global commercialization. Plans also include establishing international standards for albumin derived from lipemic plasma to ensure global recognition and acceptance. 

• Facebook
• Twitter
• Line